These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset. Lantz M; Planck T; Asman P; Hallengren B Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511 [TBL] [Abstract][Full Text] [Related]
9. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity. Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922 [TBL] [Abstract][Full Text] [Related]
10. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe. Ramos HE; Diehl LA; Camacho CP; Perros P; Graf H; Clin Endocrinol (Oxf); 2008 Dec; 69(6):951-6. PubMed ID: 18462263 [TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy. Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M Clin Endocrinol (Oxf); 2016 Nov; 85(5):805-812. PubMed ID: 27256639 [TBL] [Abstract][Full Text] [Related]
12. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy. Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772 [TBL] [Abstract][Full Text] [Related]
13. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Perros P; Dayan CM; Dickinson AJ; Ezra D; Estcourt S; Foley P; Hickey J; Lazarus JH; MacEwen CJ; McLaren J; Rose GE; Uddin J; Vaidya B Clin Med (Lond); 2015 Apr; 15(2):173-8. PubMed ID: 25824071 [TBL] [Abstract][Full Text] [Related]
14. High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study. Sabini E; Mazzi B; Profilo MA; Mautone T; Casini G; Rocchi R; Ionni I; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M Thyroid; 2018 Mar; 28(3):386-394. PubMed ID: 29336220 [TBL] [Abstract][Full Text] [Related]
18. Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study. Lanzolla G; Sabini E; Profilo MA; Mazzi B; Sframeli A; Rocchi R; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M J Endocrinol Invest; 2018 Dec; 41(12):1417-1423. PubMed ID: 29923059 [TBL] [Abstract][Full Text] [Related]
19. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy. Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103 [TBL] [Abstract][Full Text] [Related]
20. Association between interleukin 21 and Graves' disease. Jia HY; Zhang ZG; Gu XJ; Guo T; Cui B; Ning G; Zhao YJ Genet Mol Res; 2011 Oct; 10(4):3338-46. PubMed ID: 22057994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]